Quoted from http://www.forbes.com/sites/matthewherper/2013/06/04/battleground-fda-how-tomorrows-avandia-panel-could-help-shape-the-future-of-diabetes
Battleground FDA: How Tomorrow's Avandia Panel Could Help Shape The Future Of Diabetes
Matthew Herper, Forbes Staff , June 4, 2013
Avandia, once the best-selling diabetes pill on the planet, is now given only to a few thousand Americans. In much of the rest of the world it has been pulled from the market because of analyses that showed it might increase the risk of heart attacks. The controversy over the drug changed the way the Food and Drug Administration regulates diabetes medicines, resulting in steep requirements that new drugs prove they are unlikely to cause heart side effects.
Tomorrow, three years after an FDA advisory committee voted that Avandia’s use should be sharply curtailed or that the drug should be pulled, a new FDA advisory committee will take two days to reconsider that opinion. It’s possible that Avandia could go back into wider use, or that it could be withdrawn from the market entirely. Whatever happens could have far-reaching consequences for diabetes-focussed companies like Novo Nordisk, Sanofi, and Eli Lilly.